Mindpeak announces CE-mark for new product: Breast HER2 RoI
Mindpeak announces the CE-mark for another new product: Mindpeak Breast HER2 RoI (Region of Interest) supports pathologi…
Mindpeak announces the CE-mark for another new product: Mindpeak Breast HER2 RoI (Region of Interest) supports pathologi…
Die Auszeichnung „Das innovativste Produkt®“ geht zum zweiten Mal in Folge an den Covid-19-Impfstoff Comirnaty® von BioN…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…